Perrigo Company plc (PRGO)

Market Cap	1.53B -57.2%
Revenue (ttm)	4.18B -3.6%
Net Income	-1.82B
EPS	-13.10
Shares Out	138.37M
PE Ratio	n/a
Forward PE	5.09
Dividend	$1.16 (10.50%)
Ex-Dividend Date	May 29, 2026

Volume	2,351,757
Open	11.14
Previous Close	11.15
Day's Range	11.02 - 11.41
52-Week Range	9.23 - 28.44
Beta	0.54
Analysts	Buy
Price Target	16.50 (+49.32%)
Earnings Date	May 6, 2026

About PRGO

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pai...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Dec 16, 1991
• Employees: 8,100
• Stock Exchange: NYSE
• Ticker Symbol: PRGO
• Website: https://www.perrigo.com

Financial Performance

In 2025, Perrigo Company's revenue was $4.25 billion, a decrease of -2.75% compared to the previous year's $4.37 billion. Losses were -$1.43 billion, 729.7% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for PRGO stock is "Buy." The 12-month stock price target is $16.5, which is an increase of 49.32% from the latest price.

Price Target

$16.5

(49.32% upside)

Analyst Consensus: Buy